Source comparison
Is Melanotan-1 Safe According to Studies?: Safety Comparison
This table compares the documented safety profile of melanotan-1 (afamelanotide) across different use contexts based on published clinical evidence and regulatory data. FDA-approved EPP treatment (16mg implant) Nausea 31%, injection-site reactions 22%, headach
This comparison does not assign a generated winner or score.
- This table compares the documented safety profile of melanotan-1 (afamelanotide) across different use contexts based on published clinical evidence and regulatory data.
- FDA-approved EPP treatment (16mg implant)
- Nausea 31%, injection-site reactions 22%, headache 18%
- Controlled-release implant, fixed 60-day duration
- Full FDA approval with prescribing restrictions
- Well-characterized safety profile when used as directed for labeled indication
- Off-label cosmetic tanning (unregulated peptides)
- Unknown. No Phase III safety data
- Variable dosing, typically higher and more frequent
- None. Compounded or gray-market sources
- Safety cannot be established without standardized formulation and clinical monitoring
- Research applications (institutional settings)
- Dependent on protocol design
- Defined by institutional review board approval
- IRB oversight, adverse event reporting required
- Acceptable when conducted under proper ethical review with informed consent
- Injectable at-home use (purchased online)
- Unpredictable. Peptide purity and concentration not verified
- Self-administered without medical supervision
- None
- High risk. Combination of uncertain product quality and lack of dermatological screening